Competitive Landscape Analysis

GBI covers tens of thousands of global drug R&D projects, spanning the entire product life cycle, from preclinical research and clinical development to regulatory filing and post-market commercialization. Each pipeline project integrates structured, multi-dimensional information, including R&D status, clinical trials, licensing transactions, national health insurance (NHI) inclusions, and sales revenues. Supporting flexible filtering by drug name, target, indication, technology type, company, and more, the data is updated daily to ensure your intelligence remains actionable and real-time.

Analyze the competitive landscape across five core dimensions—drug, target, indication, technology, and company. The platform automatically aggregates global pipeline data and visualizes competitive positioning and development-stage distribution through intuitive charts. Whether assessing R&D activity around a target, evaluating the competitive intensity of a technology area, or comparing the pipeline portfolios of leading companies, gain a comprehensive view of the competitive landscape at a glance, significantly reducing the time and effort required for competitive analysis.

By presenting R&D stage distributions for Mainland China and overseas markets side by side, the platform highlights differences in development progress. Whether evaluating the in-licensing potential of an overseas asset or assessing the optimal timing for global expansion of proprietary assets, it provides a data-driven foundation for licensing-in and licensing-out decisions.

Set up custom tracking alerts for selected drugs, targets, indications, or companies. Receive real-time notifications whenever key milestones occur, including clinical trial phase progression, new study initiations, regulatory approvals, and others. Automated alerts eliminate manual monitoring and information lags, ensuring R&D teams stay ahead with first-hand competitive intelligence.